Abonnement à la biblothèque: Guest
Portail numérique Bibliothèque numérique eBooks Revues Références et comptes rendus Collections
Journal of Environmental Pathology, Toxicology and Oncology
Facteur d'impact: 1.241 Facteur d'impact sur 5 ans: 1.349 SJR: 0.356 SNIP: 0.613 CiteScore™: 1.61

ISSN Imprimer: 0731-8898
ISSN En ligne: 2162-6537

Journal of Environmental Pathology, Toxicology and Oncology

DOI: 10.1615/JEnvironPatholToxicolOncol.v27.i4.10
pages 245-256

Breast Cancer and Ovarian Cancer Genetics: An Update

Richard Edlich
Legacy Verified Level I Shock Trauma Center Pediatrics and Adults, Legacy Emanual Hospital; and Plastic Surgery, Biomedical Engineering and Emergency Medicine, University of Virginia Health System, USA
Catherine L. Cross
Legacy Emanuel Hospital, Portland, OR, USA
Courtney A. Wack
Legacy Emanuel Hospital, Portland, OR, USA
Margot E. Chase
Legacy Emanuel Hospital, Portland, OR, USA
Kant Y. Lin
Department of Plastic Surgery, University of Virginia Health System, Charlottesville, VA, USA
William B. Long III
Trauma Specialists LLP, Legacy Verified Level I Shock Trauma Center for Pediatrics and Adults, Legacy Emmanuel Hospital Portland, OR, USA

RÉSUMÉ

The purpose of this report on breast cancer and ovarian cancer genetics is to review the evidence for the efficacy of surveillance for early detection, bilateral prophylactic mastectomy, prophylactic oophorectomy, and chemoprevention in preventing breast cancer and improving survival of BRCA1 and BRCA2 carriers. This collective review highlights radiologic screening of patients with this genetic predisposition for cancer as well as discusses cancer risk reduction strategies and reproductive concerns in female BRCA1/2 mutation carriers. It has now been well documented that magnetic resonance imaging (MRI) of the breast has a higher sensitivity than mammography for the diagnosis of breast cancer in patients predisposed to breast cancer. We also emphasize that a new diagnostic device, molecular breast imaging (MBI), is now available and may be as sensitive as MRI. To date, this exciting technology, MBI, has not been used in studies of patients with BRCA1/2 genes. We also discuss in more detail the unique psychological ramifications of female BRCA1/2 mutation carriers. These women face unique choices regarding management of their high risk for breast and ovarian cancer that impact their reproductive options. Despite their high levels of concern, few female BRCA1/2 mutation carriers consider assisted reproduction technologies such as pregnancy surrogate, cryopreservation of oocytes or embryos, or implantation genetic diagnosis to select embryos without BCRA1/2 mutation. Further research must be undertaken to explore the risk management of patients with inherited cancer predisposition and to incorporate these preferences into clinical care.


Articles with similar content:

Breast Cancer and Ovarian Cancer Genetics
Journal of Long-Term Effects of Medical Implants, Vol.15, 2005, issue 5
Richard Edlich, Kathryne L. Winters, Kant Y. Lin
Scientific Documentation of the Relationship of Vitamin D Deficiency and the Development of Cancer
Journal of Environmental Pathology, Toxicology and Oncology, Vol.28, 2009, issue 2
William B. Long III, Shelley S. Mason, Jerry D. Giesy, Richard Edlich, Allyson L. Fisher, Margot E. Chase, K. Dean Gubler, Marni L. Foley
Biomarkers of DNA Repair and Related Pathways: Significance of Treatment in Triple-Negative Breast Cancer
Critical Reviews™ in Oncogenesis, Vol.22, 2017, issue 5-6
Wenwen Guo, Xue He, Congyang Wang, Nannan Chen, Yan Wang, Fengxia He, Li Lin
National Health Strategies to Reduce Sun Exposure in Australia and the United States
Journal of Long-Term Effects of Medical Implants, Vol.14, 2004, issue 3
William B. Long III, Richard Edlich, Daniel G. Becker, Larry S. Nichter, Theodore J. Edlich III, Jed H. Horowitz, Mary Jude Cox, Kathryne L. Winters, L. D. Britt
Theranostic Nanostructures for Ovarian Cancer
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.36, 2019, issue 4
Bankuru Navyatha, Seema Nara